Targeting the mitogen-activated protein kinase cascade to treat cancer

The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target var...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Cancer Vol. 4; no. 12; pp. 937 - 947
Main Authors Sebolt-Leopold, Judith S, Herrera, Roman
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.12.2004
Subjects
Cancer
Care and treatment
Cell Cycle
Cell Division
Cell Survival
Enzyme Activation
Genetic aspects
Humans
Mitogen-Activated Protein Kinases - antagonists & inhibitors
Mitogen-Activated Protein Kinases - chemistry
Mitogen-Activated Protein Kinases - metabolism
Models, Molecular
Neoplasms - pathology
Neoplasms - therapy
Physiological aspects
Protein Conformation
Protein kinases
Risk factors
Signal Transduction
United States
Online AccessGet full text

Cover

More Information
Summary:The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1474-175X
1474-1768
DOI:10.1038/nrc1503